Ahmedabad, January 28, 2026 Accretion Nutraveda Limited opened its SME initial public offering today, drawing early institutional interest through a strong anchor book. The company has raised ₹7.02 crore from anchor investors at the upper end of the price band, setting a constructive tone ahead of the public subscription window that closes on January 30.
Anchor Allocation Sets the Tone
Ahead of the IPO opening, Accretion Nutraveda allocated 5.44 lakh equity shares to anchor investors at ₹129 per share. The anchor tranche was led by Unicorn Fund, which accounted for the bulk of the allocation.The allocation was completed at the top of the IPO price band, indicating anchor confidence in the company’s business model and growth prospects.
| Anchor Investor | Shares Allocated | Share of Anchor Portion | Amount (₹) |
|---|---|---|---|
| Unicorn Fund | 4,66,000 | 85.66% | 6,01,14,000 |
| Radiant Global Fund Class B Participating Shares | 78,000 | 14.34% | 1,00,62,000 |
| Total | 5,44,000 | 100% | 7,01,76,000 |
IPO Details at a Glance
| Particulars | Details |
|---|---|
| Issue Opening Date | January 28, 2026 |
| Issue Closing Date | January 30, 2026 |
| Price Band | ₹122 to ₹129 per share |
| Lot Size | 1,000 shares |
| Issue Size | ₹25 crore |
| Proposed Listing | February 4, 2026 |
About the Company
Accretion Nutraveda Limited operates as a healthcare focused contract development and manufacturing organisation, producing Ayurvedic and nutraceutical products across tablets, capsules, oral liquids, powders, oils, and external preparations. The company serves domestic clients and export markets including Sri Lanka, Singapore, and the United States.With operations based out of a GMP and WHO-GMP certified manufacturing facility in Gujarat, Accretion Nutraveda follows a contract manufacturing led business model supported by domestic sales and exports. The company is scheduled to list on February 4, 2026.
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.